內克塔治療 NKTR 深 滬
已收盤 11-14 16:00:00 美东时间
56.68
+2.730
+5.06%
華盛通- 最 高57.80
- 今 開53.01
- 成交量 67.50万股
- 最 低 52.50
- 昨 收 53.95
- 總市值 10.78亿
- 52周最高 66.92
- 市盈率 靜 --
- 換手率 3.55%
- 52周最低 6.48
- 委 比 93.92%
- 總股本 1901.86万
- 歷史最高 1670.40
- 量 比 0.90
- 振 幅 9.82%
- 歷史最低 6.189
- 每 手 1
- 風險率 17.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nektar Therapeutics Reveals Promising Phase 2b Trial Results
Nektar Therapeutics ( ($NKTR) ) has provided an update. On November 8, 2025, Ne...
11-10 19:58
Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
Nektar Therapeutics shares are trading higher after the company reported better...
11-07 06:20
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
<p>Nkarta, Inc. announced it will present clinical and preclinical data on its investigational NKX019 therapy at the ACR Convergence 2025 meeting in Chicago. NKX019, an allogeneic CD19-targeting CAR-NK cell therapy, demonstrates robust depletion of pathogenic B cells and potential for treating B-cell driven autoimmune diseases. The poster presentation, titled "NKX019... in hematological malignancy and models of autoimmune disease," will be presen...
10-22 14:07
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $100 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $100 price target.
09-19 16:22
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?
Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.
09-19 02:31
Nektar Therapeutics Announces New Data From Ongoing REZOLVE-AD Phase 2b Study Of Rezpegaldesleukin At 2025 EADV Congress
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitisHigh dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments
09-18 20:47
